Abstract
NK cells are innate lymphocytes critical for immune surveillance, particularly in eradication of metastatic cancer cells and acute antiviral responses. In contrast to T cells, NK cell-mediated immunity is rapid, with spontaneous cytotoxicity and cytokine/chemokine production upon pathogen detection. The renaissance in cancer immunology has cast NK cell biology back into the spotlight with an urgent need for deeper understanding of the regulatory networks that govern NK cell antitumor activity. To this end, we have adapted and refined a series of quantitative cellular calculus methods, previously applied to T and B lymphocytes, to dissect the biologic outcomes of NK cells following stimulation with cytokines (IL-15, IL-12, IL-18) or deletion of genes that regulate NK cell proliferation (Cish), survival (Bcl2l11), and activation-induced-cell-death (AICD; Fas). Our methodology is well suited to delineate effects on division rate, intrinsic apoptosis, and AICD, permitting variables such as population half-life, rate of cell division, and their combined influence on population numbers in response to stimuli to be accurately measured and modelled. Changes in these variables that result from gene deletion, concentration of stimuli, time, and cell density give insight into the dynamics of NK cell responses and serve as a platform to dissect the mechanism of action of putative checkpoints in NK cell activation and novel NK cell immunotherapy agents.
| Original language | English |
|---|---|
| Pages (from-to) | 1341-1354 |
| Number of pages | 14 |
| Journal | Journal of Leukocyte Biology |
| Volume | 105 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 1 Jun 2019 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- checkpoints
- culture
- cytokines
- etc
- homeostasis
- NK cell
- proliferation
- quantification
- stimulation
- survival
Projects
- 2 Finished
-
Identification of E-protein complexes controlling natural killer cell fate and tumour immunity
Huntington, N. (Primary Chief Investigator (PCI)), Corcoran, L. M. (Chief Investigator (CI)), Vivier, É. (Chief Investigator (CI)) & Nicholson, S. E. (Chief Investigator (CI))
NHMRC - National Health and Medical Research Council (Australia)
1/02/19 → 31/12/19
Project: Research
-
Identification and targeting of a potent NK cell “checkpoint” in tumour immunity
Huntington, N. (Primary Chief Investigator (PCI))
NHMRC - National Health and Medical Research Council (Australia)
1/02/19 → 31/12/20
Project: Research
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver